(HealthDay News) — Receiving care at a multidisciplinary (MultiD) clinic facilitates adherence to evidence-based national treatment guidelines for prostate cancer, according to a study published online Nov. 19 in Cancer.
Chad Tang, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues analyzed 4,451 men with prostate cancer who presented to the MultiD clinic from 2004 to 2016. Nationwide trends were assessed by analyzing 392,710 men with prostate cancer diagnosed from 2004 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database.
The researchers identified similar treatment trends in the MultiD and SEER cohorts in univariate analyses. With age, there was a decrease in the use of procedural forms of definitive therapy, including brachytherapy and prostatectomy. There was a correlation seen for later year of diagnosis/clinic visit with decreased use of definitive treatments, whereas increased use was seen with higher-risk grouping. Patients with low-risk disease were more likely to receive nondefinitive therapy at the MultiD clinic than were patients in SEER, while a substantial proportion of high-risk patients in SEER did not receive definitive therapy. African-American men with intermediate- and high-risk disease were more likely to receive definitive therapy than were white men in the MultiD clinic, while the opposite was true for SEER.
“The outcomes of this study offer an important motivation to provide multidisciplinary clinical care on the national level,” Tang said in a statement.
Several authors disclosed financial ties to the pharmaceutical industry.